Genopathy
Gene-Disorder Association · Article
Gene
KRAS
KRAS Proto-Oncogene, GTPase
Manually curatedApproved treatment annotated
Association Review

In brief

The association between KRAS (KRAS Proto-Oncogene, GTPase) and Cervical Cancer is reported, with clinical genetic testing available.

Sources 1
Clinical variants 0
Symptoms 3
Compounds 7
Trials 225of 12,277 via KRAS compounds
Publications 1
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

1 source

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
KRAS

The gene

2 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Cervical Cancer

The disorder

15 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
Phenotype

Clinical features

2 clinical features

The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.

Request access
06
Interventions

Therapeutics

7 compounds & drugs

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
07
Human studies

Clinical trials

12,277 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
08
Literature

Reading

1 publication

Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.

Request access
09
Provenance

References & sources

8 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access